




EVOLUTION OF THE CD4 COUNT IN THE 
FIRST 12 MONTHS FOLLOWING INITIATION 
OF ANTIRETROVIRAL THERAPY IN A SOUTH 










EVOLUTION OF THE CD4 COUNT IN THE 
FIRST 12 MONTHS FOLLOWING INITIATION 
OF ANTIRETROVIRAL THERAPY IN A SOUTH 




MFUNDO FALETHU MATHENJWA 
 
Thesis submitted in part-fulfilment of the requirements for the degree of Master of Medicine 
(Medicine) in the School of Clinical Medicine, University of KwaZulu-Natal 
Supervisor 
Prof Richard J Hift 
Prof Nombulelo Magula 
School of Clinical Medicine, University of KwaZulu-Natal, South Africa 
  
DECLARATION  
I, Mfundo F Mathenjwa, declare that: 
i. The research reported in this dissertation, except where otherwise indicated, is my 
original work. 
ii. This dissertation has not been submitted for any degree or examination at any other 
university. 
iii. This dissertation does not contain other persons’ data, pictures, graphs or other 
information, unless specifically acknowledged as being sourced from other persons. 
iv. This dissertation does not contain other persons’ writing, unless specifically 
acknowledged as being sourced from other researchers. Where other written sources 
have been quoted, then: 
a. their words have been re-written, but the general information attributed to them 
has been referenced; 
b. where their exact words have been used, their writing has been placed inside 
quotation marks, and referenced. 
v. Where I have reproduced a publication of which I am an author, co-author or editor, I 
have indicated in detail which part of the publication was written by myself alone and 
have fully referenced such publications. 
vi. This dissertation does not contain text, graphics or tables copied and pasted from the 
Internet, unless specifically acknowledged, and the source being detailed in the 





Dr MF Mathenjwa 
Candidate 
 Prof RJ Hift 
Supervisor 
11 January 2017  
i
DEDICATION 




I express my appreciation to my supervisors, Professors Richard Hift and Nombulelo Magula.  
  
iii
TABLE OF CONTENTS 
Declaration .............................................................................................................................. i 
Dedication .............................................................................................................................. ii 
Acknowledgments................................................................................................................. iii 
Table of Contents .................................................................................................................. iv 
Abbreviations ......................................................................................................................... v 
Pagination and Referencing .................................................................................................. vi 
Chapter 1: Introduction .......................................................................................................... 1 
Literature Review .............................................................................................................. 2 
CD4 count and HIV infection....................................................................................... 2 
Viral load and viral suppression ................................................................................... 3 
Assessing response to antiretroviral therapy ................................................................ 3 
Immune reconstitution inflammatory syndrome .......................................................... 4 
Antiretroviral therapy in South Africa ......................................................................... 4 
Current South African practice in initiating adult patients on antiretroviral therapy ... 5 
The current study ............................................................................................................... 6 
Background to the current study................................................................................... 6 
Research question, Hypothesis, Aims, Objectives and Methodology .......................... 7 
References ......................................................................................................................... 9 
Chapter 2: Evolution of the CD4 count in the first 12 months following initiation of 
antiretroviral therapy in a South African public-sector patient population ...... 14 
Appendices ........................................................................................................................... 41 





AIDS Acquired immunodeficiency syndrome 
ART Antiretroviral therapy 
CCR5 C-C Chemokine receptor 5 
HIV Human immunodeficiency virus 
IRIS Immune reconstitution inflammatory syndrome 
NNRTI Non-nucleoside reverse transcriptase inhibitor 
NRTI Nucleic reverse transcriptase inhibitor 
TB Tuberculosis 
UTT Universal test and treat 
WHO World Health Organisation 
v
PAGINATION AND REFERENCING 
The pages of the dissertation are numbered consecutively at the bottom of each page. Chapter 
2, which is presented in manuscript form is additionally numbered separately in the top right 
corner. 
The introductory chapter, Chapter 1, is referenced with bold numbers in square brackets thus: 
[1]. The bibliography is found at the end of that chapter. Chapter 2, which is presented in 
manuscript form, is separately referenced with superscript numerals thus: 1. The approved 
protocol (Appendix 1) is also separately referenced, and the bibliography will be found at the 










CD4 count and HIV infection 
The CD4+ T lymphocyte is the primary target of HIV infection [1]. The CD4 count reflects the 
extent of the resultant immune suppression. It is calculated from the CD4 cell percentage and 
total white blood cell count. The CD4 count reference values vary considerably amongst 
different laboratories [2]. For most laboratories, the mean CD4 count is of the order of 500-
1300 cells/mm3. Untreated HIV-infected individuals, experience a yearly CD4 count decline 
of 50-80 cells/mm3. The pattern of decline is usually slow, taking ten years for a newly infected 
person to progress to the acquired immunodeficiency syndrome (AIDS). There is however 
great variation among individuals [3-6]. For some patients, known as rapid progressors, disease 
progression occurs within a couple of years. A major criterion for this is the demonstration of 
more than two CD4 T cell measurements below 350 cells/mm3 within 3 years after 
seroconversion, with no value ≥ 350/mm3. By contrast, long-term non-progressors show little 
or no decline in CD4 count over an extended period [5]. 
Among those with HIV infection, the CD4 count is therefore the major indicator of 
immunodeficiency. It was for many years the principal factor in deciding whether to initiate 
antiretroviral therapy (ART) [7,8]. More recently there been a major shift in this approach, with 
initiation of ART being recommended for all HIV-positive individuals, irrespective of CD4 
count [9,10]. The CD4 count is an essential parameter in monitoring both the progress of the 
disease and the response to ART. Initiation of prophylaxis against opportunistic infections is 
typically dependent on demonstration of a low CD4 count [7]. Conversely, viral suppression 
typically leads to quantitative and qualitative immunological reconstitution[11-13]. 
A sustained CD4 count greater than 200 cells/mm3 dramatically reduces the risk of 
opportunistic infections such as cytomegalovirus, Pneumocystis jiroveci, Mycobacterium 
avium complex, Toxoplasma gondii, and Cryptococcus neoformans, allowing primary and 
secondary prophylaxis for many opportunistic infections to be discontinued [14,15]. For this 
reason, a CD4 count of less than 200 cells/mm3 has traditionally been used as an indication for 
prophylaxis against Pneumocystis jiroveci pneumonia. International best practice however now 
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suggests a threshold of 350 cells/mm3 [16]. The risk of tuberculosis (TB), though markedly 
reduced by ART, remains higher than that in the general population [17-19]. It is recommended 
that all patients receiving ART in South Africa should be considered for isoniazid prophylaxis 
[15], since prophylaxis has been shown to result in a 37% reduction in incident TB [20]. 
Patients who are diagnosed with cryptococcal meningitis should remain on prophylactic 
fluconazole for a minimum of 1 year following acute treatment. This may be discontinued in 
patients on ART who demonstrate viral suppression and a CD4 count>100 cells/mm3 for at 
least 3 months [21]. However, even with control of the conventional opportunistic infections, 
there is still a challenge in attaining sufficient immunocompetence to prevent non-conventional 
opportunistic complications such as HIV-associated cardiomyopathy, steatohepatitis and HIV 
associated nephropathy [22,23]. 
Viral load and viral suppression 
The HIV-1 viral load is an indication of the number of copies of HIV-1 RNA per millilitre of 
plasma. Despite HIV being an intracellular pathogen, the HIV-1 viral load in plasma is a 
precise barometer of the extent of infection and the stage of viral replication [24]. It is essential 
in gauging virological response to pharmacotherapy. The HIV-1 viral load measurement 
indicates the number of copies of HIV-1 RNA per millilitre of plasma. Although HIV 
ultimately resides within cells, the plasma measurement is an accurate reflection of the burden 
of infection and the magnitude of viral replication It is critical in monitoring virological 
response to therapy. The primary aim of combination antiretroviral therapy is maximal and 
durable suppression of viral replication [7]. This delays development of drug resistant 
mutations, preserves and increases CD4 cells and ultimately results in better clinical outcomes. 
A failure to achieve viral suppression is an indication for a switch to a second or third line 
ART regimen provided that compliance has been addressed [7]. 
Assessing response to antiretroviral therapy 
Failure of suppression of viral load is a critical step in the early recognition of treatment failure 
since a rise in CD4 count and a deterioration in clinical response typically take much longer to 
develop [7]. With an effective ART regimen, viral suppression to undetectable levels should 
be achieved within 3 to 6 months after initiation of therapy [2,25]. Frequent monitoring of CD4 
counts, especially in those with higher counts, above 300 cells/mm3, is generally not required 
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in patients with consistently suppressed viral loads. South African practice has been to measure 
the CD4 count annually in patients receiving ART whose condition is otherwise satisfactory 
[26]. The most recent guidelines however recommend that annual CD4 count measurements 
should be regarded as optional in patients on ART with a CD4 count >500 cells/mm3 [7]. 
The detection of treatment failure is an important part of the management of patients receiving 
ART. Virological failure is variously defined as the inability to achieve or maintain suppression 
of viral replication to an HIV RNA level less than 200 copies/ml [7], or as a viral load above 
1000 copies/ml based on two consecutive viral load measurements three months apart in a 
patient who has been on ART for at least six months and has had adherence support [27]. 
Immunological failure is indicated by a CD4 count ≤ 250 cells/mm3 following clinical failure 
(see below), or a persistent CD4 count below 100 cells/mm3. Clinical failure is defined by the 
development of new or recurrent clinical conditions indicative of severe immunodeficiency 
after 6 months of effective treatment [27]. 
Immune reconstitution inflammatory syndrome 
The immune reconstitution inflammatory syndrome (IRIS) is characterised by strengthening of 
a previously weak immune system resulting in paradoxical clinical deterioration due to a 
recovery in the immune system, allowing it to mount a strong inflammatory response to a 
pathogen. It is usually self-limiting and does not require discontinuation of ART, though it may 
occasionally be life-threatening [28,29]. In patients not on ART presenting with cryptococcal 
meningitis or TB meningitis, initiation of ART is typically deferred for a short period to lessen 
the risk of IRIS [30]. National guidelines in South Africa recommend a 2-week interval 
between initiating antituberculous therapy and initiating ART [31]. 
Antiretroviral therapy in South Africa 
South Africa has the highest HIV prevalence in the world, and additionally the largest ART 
program [32,33]. The national ART programme in South Africa was launched in April 2004. 
Initially antiretroviral therapy was made available to all public-sector adult patients with a CD4 
count of less than 200 cells/mm3 as well as those with Stage 4 clinical disease. In 2010 the 
program was expanded to include pregnant and TB-co-infected subjects with a CD4 count of 
less than 350 cells/mm3, and in August 2011, to enrol all patients with a CD4 count of less than 
350 cells/mm3 in line with the then World Health Organisation HIV Guidelines. As of April 
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2013, all patients co-infected with drug-sensitive or resistant TB were initiated on ART 
irrespective of CD4 count. This coincided with the introduction of fixed drug combination ART 
for patients who are initiated on ART for the first time [7,8]. This helps reduce the pill burden, 
thus facilitating compliance. A protocol for the phased introduction of fixed drug combination 
ART to patients with other co-morbidities, such as TB and cryptococcal meningitis was 
developed, resulting in classification of patients according to different eligibility groups. HIV 
positive women who are pregnant or breastfeeding, patients with a low CD4 of less than 200 
cells/mm3 patients with stage 4 illness irrespective of CD4 count and patients co-infected with 
TB with CD4 count <50 cells/mm3 were all now be eligible for initiation of ART within seven 
days, bringing the South African guidelines into convergence with the WHO 2013 consolidated 
guidelines on use of antiretroviral drugs [34]  
With effect from 1 September 2016, in terms of a Universal Test and Treat (UTT) policy, all 
HIV-positive individuals presenting to South African public health institutions are eligible for 
immediate initiation of ART, with certain vulnerable groups expressly prioritised for rapid 
enrolment [35]. The recent national UTT policy brings South African practice into conformity 
with recent World Health Organisation guidelines [10] and the 2016 update to the 2014 USAID 
guidelines [7], both of which recommend that ART should be initiated among all adults with 
HIV regardless of CD4 count. South Africa is committed to the 90-90-90 targets set by the 
Joint United Nations Programme on HIV/AIDS(UNAIDS) [36], which state that by 2020, 90% 
of all people living with HIV will know their HIV status, 90% of all people living with 
diagnosed HIV infection should receive sustained ART, and 90% of all people receiving ART 
will have viral suppression. 
Current South African practice in initiating adult patients on antiretroviral 
therapy 
South African patients in whom ART is initiated are currently managed in accordance with the 
South African National consolidated guidelines of 2015 [37], as modified by the September 
2016 policy document mandating universal test and treat [35]. Patients are advised on how to 
avoid HIV transmission to sexual partners and children. They are initiated on isoniazid 
prophylaxis if asymptomatic for TB. They are also provided with counselling on nutrition and 
contraception and to do annual Papanicolaou smear. 
Patients are screened for syphilis and active TB at the time of first diagnosis. Baseline CD4 
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cell count and biochemical profile including full blood count, renal and liver function tests are 
performed. Follow up is subsequently every 12 months for clinical and biochemical review. 
This entails screening for opportunistic infections and drug adverse effects. Of paramount 
importance is the 12-monthly monitoring of immunologic and virologic response, which 
involves monitoring of the CD4 count and viral load. 
A typical first-line South African antiretroviral therapy regimen includes two nucleoside 
reverse transcriptase inhibitors (NRTIs), currently tenofovir, lamivudine or emtricitabine, and 
one non-nucleoside reverse transcriptase inhibitor (NNRTI), currently efavirenz [37]. 
Stavudine, initially widely used as first-line therapy, has been phased out with all patients 
currently on a stavudine containing regimen being moved to a tenofovir-containing regimen, 
provided there are no contraindications. Stavudine is to be used only under specific 
circumstances, for example in patients with renal failure and severe anaemia, in which case the 
use of tenofovir and zidovudine are respectively contra-indicated, Abacavir may also be used 
under the above circumstances if stavudine is contraindicated [37]. This agent is however 
costly and carries a small risk of hypersensitivity reactions. The use of nevirapine has been 
superseded by the use of efavirenz given the more favourable toxicity profile of the latter. 
Failure of this regimen may require switching to a protease inhibitor (PI)-containing second 
line regimen (ritonavir/lopinavir combination). This is done with expert advice. Failing any 
second line regimen, patients are referred for specialist opinion for a regimen based on 
genotype resistance testing [35]. These patients receive supervised care and are managed 
centrally by the National Department of Health. A third line regimen comprises 
darunavir/ritonavir, emtricitabine or lamivudine, tenofovir or zidovudine with or without 
raltegravir with or without etravirine, based on genotype scoring [7]. 
THE CURRENT STUDY 
Background to the current study 
South Africa has adopted the UTT strategy as of 1 September 2016 [35]. This might seem to 
make the use of CD4 count as a tool in management somewhat redundant as patients are 
initiated on ART regardless of CD4 count. However, the continued importance of CD4 testing 
at both initiation and subsequently has been described in the preceding sections; principally in 
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terms of the decision to initiate and withdraw prophylaxis for opportunistic infections [21] and 
the accumulating evidence that a low initial CD4 count and immunological failure during 
therapy are associated with worse outcomes in the long-term, even in the presence of adequate 
viral suppression [38]. 
The problems inherent in administering a public-sector ART programme of the magnitude of 
the South African programme are acknowledged [33], and there is expected value in studying 
the trend in CD4 count in response to ART administered in a South African public-sector 
setting. In this study, the candidate set out to examine the extent of the increase in CD4 count 
in the first year after initiation of ART in a local setting, and to examine some of the factors 
which may affect it. 
Research question 
 What is the observed increase in CD4 count after 12 months’ ART therapy in patients 
attending a large South African public hospital? 
Hypothesis 
 Properly prepared patients on South African public hospital who demonstrate viral 
suppression will demonstrate significant improvement in CD4 count.  
Aims 
 To determine the magnitude of the increase in CD4 count in patients demonstrating 
viral suppression following 12 months ART, the association of this with clinical well-
being and its association with other parameters which might remote or retard immune 
reconstitution. 
Objectives 
 To measure the increase in CD4 count in patients on ART 
 To correlate the increase in CD4 count with changes in haemoglobin concentration and 
weight 
 To document factors which might influence the magnitude of the CD4 response: sex, 
CD4 count at time of initiation of ART 
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 To document and describe the incidence of opportunistic infections in patients on ART 
with viral suppression 
 To document the incidence of IRIS in patients on ART 
Methodology 
The candidate conducted a retrospective chart review of patients enrolled at the Philani Clinic 
(the HIV clinic attached to King Edward VIII Hospital, Durban, South Africa). A power 
calculation indicated that 230 subjects were necessary to demonstrate a difference in CD4 count 
between baseline and one year, significant at the 5% level with a beta error of 20%. A pro-
forma data capture sheet was designed and used to facilitate the collection of all data relevant 
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We studied the 12-month clinical and CD4 count response in patients newly initiated on 
antiretroviral therapy in a South African public hospital. 
Background 
The CD4 count and viral load are closely linked to human immunodeficiency virus (HIV)-
related illness and mortality. Numerous studies have shown that initiation of ART can improve 
quality of life and longevity in HIV-1 infected patients. 
Methods  
We performed a retrospective chart review of 257 patients initiated on ART over one year in 
whom viral load suppression was documented. We monitored the change in CD4 count, viral 
load, weight and haemoglobin concentration over the first 12 months, and documented the 
incidence of opportunistic infections and of the immune reconstitution inflammatory syndrome 
(IRIS). 
Results 
Of 257 patients, 219 had complete viral suppression; 30 showed incomplete suppression with 
a final load <400 copies/ml and 8 subjects had a final viral load <1000 copies/ml. The mean 
CD4 count at baseline was 139 [IQR 63-195] cells/mm3. The CD4 count at baseline was 
significantly lower in males (90 [IQR 24-180] cells/mm3) than females (148 [IQR 88-199] 
cells/mm3). Opportunistic infections were observed in 87 of 257 patients (33.9%) and were 
significantly more frequent in males (52%) than females (27%). Sixty-eight patients had 
tuberculosis (TB); 17 had cryptococcal meningitis (17) and 13 had oesophageal candidiasis. 
Opportunistic infections were significantly more common in males and in patients with lower 
CD4 counts at entry. Seven patients developed IRIS. All had TB; two presented additionally 
with cryptococcal meningitis. Comparison of values at 12 months with baseline showed a 
significant increase in CD4 count from 139 to 327 cells/mm3 (p<0.0001), weight (67.3 kg-71.4 
kg) (p<0.0001) and haemoglobin (11.1-11.9 g/dL) (p<0.0001). The increase in CD4 count was 
17
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similar across the full range of baseline counts, including those with an initial count less than 
50 cells/mm3. The probability of a satisfactory response in CD4 count was not affected by the 
presence of an opportunistic infection. Patients treated with nevirapine showed a significantly 
higher eventual CD4 count, even after controlling for the baseline CD4 count, than patients 
treated with efavirenz (p=0.015).  
Conclusion 
Males present to our service with a lower baseline CD4 count and higher rate of opportunistic 
infections than females. In patients in whom complete or partial viral suppression was obtained, 
initiation of ART resulted in a significant increase in CD4 count in patients irrespective of age, 
sex, baseline CD4 counts and the presence of an opportunistic infection. We conclude that 
antiretroviral therapy is highly effective in our population and comparable in efficacy to 





The CD4+ T lymphocyte is the primary target of HIV infection1, and the CD4 count reflects 
the extent of the resultant immune suppression. The primary aim of combination antiretroviral 
therapy (ART) is maximal and sustained suppression of viral replication2. Most patients who 
achieve and maintain an undetectable HIV plasma RNA level on ART will demonstrate a 
substantial increase in their peripheral CD4 count2-4. A sustained CD4 count greater than 200 
cells/mm3 dramatically reduces the risk of opportunistic infections, and a treatment-associated 
rise in CD4 count will permit the discontinuation of prophylaxis for opportunistic infections 
such as Pneumocystis jiroveci, Toxoplasma gondii, and Cryptococcus neoformans5,6. 
Immune reconstitution in response to ART occurs most quickly in the first two years after 
commencing ART, and the CD4 count rises more slowly thereafter7,8. An average increase of 
93-151 cells/mm3 over baseline values has been reported for the first six months of therapy 
with a subsequent average increase of 22-36 cells/mm3 per year for the first four years of 
therapy thereafter9-11. ART-induced increases in CD4 count are more variable from patient to 
patient than is the reduction in viral load, and may be affected by factors such as the elapsed 
time between HIV seroconversion and initiation of ART, pre-ART CD4 count, the degree of 
viral suppression, the presence of clinical AIDS before initiation of treatment, hepatitis C 
coinfection and the ∆32 CCR5 genotype3,10,12-14. Though in general the type of regimen used 
is not thought to be a major predictor of the likelihood of a poor immunological response15,16, 
it has been suggested that zidovudine-containing regimens and male sex may be associated 
with lower responses17. Concurrent opportunistic infections, commonly tuberculosis (TB), may 
blunt ART-induced CD4 count improvement. A history of HIV-associated TB prior to 
commencement of ART18 or incident TB during ART17 are also reportedly associated with 
lower CD4 count recovery. This has however not been the experience in South Africa where 
patients presenting with TB at the time of initiation of ART had similar increases in CD4 in 
comparison with other patients19. 
A minority of individuals do not achieve full immune reconstitution, even after prolonged viral 
suppression8, particularly those in whom initiation of ART was delayed until after their CD4 
cell count had dropped below 200 cells/mm3 2,20,21. Studies of the recovering immune response 
show this to be a complex process22, and the mechanisms underlying incomplete 
immunological recovery are not understood. Immune activation as measured by co-expression 
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of CD38 and HLA-DR on T-cells is a strong predictor of CD4 cell loss and disease progression 
in untreated HIV infection23-25, and this may be a feature of retarded immunological recovery 
in response to ART as well26,27. Incomplete immunological recovery has clinical consequences, 
and failure to restore a normal CD4 count following ART is associated with increased 
morbidity and mortality28. 
The addition of CD4 count and viral load monitoring to clinical monitoring is associated with 
improved health and survival2,29. Frequent monitoring of CD4 count is in general not required 
in patients with consistently suppressed viral loads, particularly where the CD4 count is above 
300 cells/mm3. South African practice has been to measure the CD4 count annually in patients 
receiving ART whose condition is otherwise satisfactory30; the updated US guidelines continue 
to recommend this for otherwise stable patients receiving ART beyond two years with a CD4 
count below 500, but indicate that it is optional for patients with a CD4 count above 5002. 
CD4 count thresholds were for many years the principal factor in deciding when to initiate 
ART2,31. Currently ART is recommended for all HIV-positive individuals, irrespective of CD4 
count32,33, and this has now been incorporated into South African public sector guidelines as 
part of the universal test and treat (UTT) policy34. While CD4 count is no longer a factor in 
initiating treatment, it retains its importance in predicting susceptibility to opportunistic 
infections and in predicting long-term outcome even in patients with a satisfactory virological 
response to ART28,35. 
The South African ART programme is the largest in the world and, given the country’s status 
as a developing economy, successful program delivery is challenging36. We believe there is 
value in studying the trend in CD4 count in response to ART administered in a South African 
public-sector setting. In this study, we describe the extent of the increase in CD4 count in the 
first year after initiation of ART in a local setting, and examine some of the factors which may 
affect it. 
SUBJECTS AND METHODS 
We performed a retrospective chart review of patients enrolled at the Philani HIV Clinic at 
King Edward VIII Hospital, Durban, South Africa. We included patients 18 years and older, 
commenced for the first time on ART from January 2010, who had satisfactorily completed at 
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least 12 months of follow-up, including a subsequent viral load, CD4 count and clinical and 
laboratory data. We excluded patients with incomplete data, poor adherence to medication 
(which we defined as a failure to attend any scheduled visit to the hospital pharmacy for 
treatment collection), documented psychiatric illness or a final viral load greater than 1000 
copies/ml. The study was adequately powered to demonstrate a difference in pre-treatment and 
post-treatment CD4 count at the 5% level with a beta error of 20%.  
Age, sex, viral load, CD4 count, weight, haemoglobin concentration and regimen type were 
documented at initiation and on completion of 12 months’ follow-up. We documented any 
preceding or intercurrent opportunistic infections, and any episode of the immune 
reconstitution inflammatory syndrome (IRIS). ART was commenced in patients with TB 
following at least 2 weeks of anti-tuberculous treatment. 
Ethical considerations 
All data were anonymised. Individual patient consent was not required for this retrospective 
review. The study was approved by the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal (Approval Number BE 063/12), and was performed with the 
permission of Hospital Management. 
Data management and statistical analysis 
All data were entered on an Excel spreadsheet (Microsoft Corporation, Redmond WA). The 
observed change in CD4 count was correlated with demographic data (age, sex and race), 
presence of intercurrent infection, WHO HIV clinical stage, baseline CD4, ART adherence as 
reflected by clinic attendance, and use of other drugs known to interact with ART. Normally 
distributed data are reported as mean (standard deviation, SD) and were tested for significance 
using Student’s t-test. Non-parametric data are reported as the median [interquartile range, 
IQR] and were tested for significance using the Mann-Whitney U test and Kruskal Wallis 
ANOVA. Correlations were tested using the Spearman rho test. Statistical calculations were 
performed using MedCalc version 16.8 (MedCalc Software bvba, Ostend, Belgium). A p value 




We reviewed the records of 257 patients who had received ART for at least one year and 
demonstrated viral load suppression to less than 1000 copies/ml. All patients were of African 
ethnicity and none had received prior ART.  
Patients were treated according to standard protocols in force at the time of initiation of ART. 
All received lamivudine, with either stavudine or tenofovir as the nucleoside reverse 
transcriptase inhibitor (NRTI), and nevirapine or efavirenz as the non-nucleoside reverse 
transcriptase inhibitor (NNRTI). Baseline parameters are shown in Table 1. There was no 
significant difference in age between males and females. Median baseline CD4 count was 139 
[IQR 63-195] cells/mm3 and was significantly lower in males than females (p< 0.003). 
Eighty-seven of the 257 patients (33.9 %) had experienced opportunistic infections prior to 
initiation of treatment (Table 2). The three most prevalent opportunistic infections were TB 
(68), of which 24 were disseminated or extrapulmonary TB, cryptococcal meningitis (17) and 
oesophageal candidiasis (13). Patients who had previously experienced an opportunistic 
infection had a significantly lower CD4 count at entry (64 [IQR 24-168] cells/mm3) then those 
who had not (161 [IQR 112-202] cells/mm3, p=0.0001) and opportunistic infections were 
significantly more frequent in males (52 %) than females (27%) (p=0.001). 
Viral suppression in response to ART was a requirement for inclusion in our study. 219 subjects 
showed complete viral suppression; a further 30 showed incomplete suppression with a final 
viral load <400 copies/ml, and in a further 8 subjects, <1000 copies/ml. Males and females did 
not differ in their probability of an incomplete response (p=0. 84). 
We demonstrated a highly significant increase in CD4 count, weight and haemoglobin over the 
first 12 months of therapy (Table 3). Age did not correlate with the baseline CD4 count 
(p=0.74) or with the increase in CD4 count on therapy (r=-0.114, p=0.07). The probability of 
a satisfactory response in CD4 count was not affected by the presence of an opportunistic 
infection (p=0.14). 
There was a highly significant correlation between the CD4 count at baseline and that reached 
at 12 months (Spearman’s rho =0.643, p<0.0001). Though there was no correlation between 
the absolute increase in CD4 count and baseline CD4 level (p=0.17), with a mean increase of 
approximately 200 cells/ml in all patients with an initial CD4 count below 350 (Table 5), when 
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the increase is expressed as a percentage over baseline. This equates to a proportionately greater 
increase in patients with initially low values (Spearman’s rho=-0.74, p<0.0001). A 
significantly larger increase in weight was observed in patients with lower CD4 counts at 
baseline (Spearman rho=-0.17, p=0.006). There was no significant correlation between initial 
CD4 count and change in haemoglobin (p=0.43). 
Seven of the 257 study patients (2.7%) developed the immune response inflammatory 
syndrome (IRIS) while on therapy. Five of the seven were associated with TB and 2 with both 
TB and cryptococcal meningitis. Patients who developed IRIS had a lower median baseline 
CD4 count (43 [IQR 37-141] cells/mm3, n=7) than those who did not (141 [IQR 66-196] 
cells/mm3, n=250, p=0.06).  
Eleven patients (4.3%) met numeric WHO criteria37 for immunological treatment failure: 6 in 
whom the CD4 count at 12 months was less than 100, and five in whom the final CD4 count 
was lower at 12 months than at initiation. Four of these had received treatment for active TB 
during the period of ART. However, in all cases treatment had been successfully terminated at 
least 5 months prior to the final CD4 estimation, and the low CD4 count cannot be ascribed to 
a TB-associated reduction in CD4 count. All 11 therefore represent true immunological 
treatment failure. We were unable to show a significant difference in the extent of weight gain 
(p=0.90) or haemoglobin rise (p=0.16) between those with a satisfactory immunological 
response and those without. 
Increases in the CD4 count were not significantly lower for patients with an incomplete 
virological response in comparison with those with a complete response (p=0.13). While the 
final CD4 count was lower in those who did not achieve a complete virological response (272 
[IQR 201-408] cells /mm3, n=38) versus those who did (332 [IQR 242-431] cells/mm3, n=219) 
the result is not significant (p=0.09). 
Patients treated with tenofovir had a significantly higher CD4 count at baseline (148 [IQR 69-
199] cells/mm3, n=186) than patients who received stavudine (113 [IQR 48-180], n=60) or 
zidovudine (91 [IQR 50-203], n=11) (p=0.05), probably representing the later introduction of 
tenofovir into the ART coincidental with initiation of patients on ART at higher CD4 counts. 
The increase in CD4 count across the three drugs did not differ significantly (p=0.7) and the 
post-treatment CD4 count (p=0.85) did not differ significantly between the three drugs. 
Patients on nevirapine showed a significantly greater increase in CD4 count with a median 
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increase of 210 cells/mm3 [IQR 152-277], n=109) than those on efavirenz (157 [IQR 116-248], 
cells/mm3, n=148) (p=0.001). Patients treated with nevirapine reached a higher post-treatment 
CD4 count (285 [IQR 202-383] cells/mm3) than those on efavirenz (210 [IQR 152-277] 
cells/mm3, p<0.0001). Though the baseline CD4 count was lower in patients treated with 
efavirenz (median CD4 count 114 [40-184] cells/mm3) than in patients treated with nevirapine 
(168 [IQR 124-199] cells/mm3, p<0.0001); two-way factorial ANCOVA indicates that the 
contribution of nevirapine to a higher eventual CD4 count is significant even after controlling 
for the baseline CD4 count (p=0.015). 
DISCUSSION 
ART is a highly effective treatment for HIV-infected individuals which routinely improves 
both life expectancy and the quality of life in those patients who maintain adequate viral 
suppression38,39. An additional expected benefit is the significant reduction in viral 
transmission, a recent publication has shown that there is a 93% reduction in risk of infection 
of a link partner in subjects receiving early ART rather than delayed ART in the developing 
world40; and high rates of protection have been shown, as well as a reduction in mortality, 
had been shown in a deprived rural area of KwaZulu-Natal41. 
A feature of our patient cohort is the advanced degree of immunodeficiency at the time of ART 
initiation, with almost all patients having enrolled with a CD4 count less than 200 cells/mm3. 
34% had experienced opportunistic infections prior to enrolment, including a high incidence 
of pulmonary TB in addition to the classic extrapulmonary TB, disseminated TB and other 
AIDS-defining illnesses such as cryptococcal meningitis and oesophageal candidiasis. This is 
still a common experience in resource-limited countries42. The average age of our patient 
cohort was 37 years, which corresponds with the peak of the sexually active population of 15-
49.  
Fewer males present for ART at an early stage of infection. Male sex has been found to be a 
significant determinant of a late presentation in Durban43, in sub-Saharan Africa and in 
developing countries more generally44. Males typically present with advanced disease; there 
is some evidence that the gap may be increasing even as the proportion of patients presenting 
at an advanced stage for initiation of therapy decreases42. This is reflected in our cohort 
where the baseline CD4 count was significantly lower for males than for females.  
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As with other studies from resource-limited settings, the results of our study are 
encouraging42. There is a significant mean increase in CD4 count of 188 cells/mm3 after 12 
months, and this was associated with gains in weight and haemoglobin suggesting an 
improvement in general health. Only 11 of 257 study patients met the WHO criteria for 
immunological treatment failure, indicating a 96% immunological response rate. A successful 
outcome was independent of age, sex, initial viral load (measured in some but not all 
participants), the baseline CD4 count and the presence of preceding opportunistic infections 
or of treatment regimen. Interestingly however, patients with immunological failure were no 
less likely to gain weight or show an increase in haemoglobin. We were unable to show a 
correlation and the extent of the increase in CD4 count with age or sex in contrast to the 
findings of Nash et al. 42. We did however find a highly significant correlation between the 
CD4 count reached at 12 months and the baseline CD4 count. This is in line with the findings 
of Nash et al. in a multinational study, who found that this differentiation persists with time, 
and that those who start treatment with a lower CD4 count remain at a persistent 
disadvantage. 
Our results also show that the change in recommended regimen from stavudine, with its 
multiple metabolic complications, to tenofovir, which has a much lower toxicity profile, was 
not accompanied by any decrease in efficacy, thus confirming previous findings45. Our results 
do however suggest that nevirapine may be more effective in increasing the CD4 count than 
is efavirenz. This is unexpected, since previous studies in Ethiopia46 and Thailand47 have 
suggested comparable responses for efavirenz and nevirapine. The use of nevirapine is now 
discouraged in South Africa, given its toxicity profile. Were our observations to be confirmed 
in further studies however, we may have to consider the possibility that the shift from 
nevirapine is accompanied by some loss in efficacy. 
The findings of this analysis are strengthened by the relatively homogeneous study 
population receiving treatment at a single facility using standardised clinical protocols. 
Patients were all ART-naïve and received a standard triple-drug regime with uniform follow-
up time points. Quality-assured laboratory assays were all performed in a single nationally 
accredited laboratory. Our patient population was treated under the government ART roll-out 
programme and data are therefore likely to be generalizable to other ART programmes in 
sub-Saharan Africa.  
A limitation of our study is that we only followed patients who demonstrated virological 
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suppression. We are therefore unable to comment on that cohort of patients who failed to 
respond to ART. We limited our analysis of CD4 cell recovery to the first 12 months of ART; 
long-term outcomes have not been determined. Nor have we studied the effects of parameters 
such as genetic determinants (e.g. the protective ∆32 CCR5 genotype) on CD4 response 
curves. Though our results suggest a greater effect on CD4 count for nevirapine than 
efavirenz, this is a finding which is best confirmed in a proper randomised controlled trial. 
Conclusion 
Patients treated in the South African public health sector may be regarded as disadvantaged in 
comparison with many other groups who have been studied, in that they have, at least until 
recently, been enrolled on treatment when already significantly immunosuppressed, and with 
a high likelihood of already having developed opportunistic infections44. A recent study from 
Johannesburg found that patients whose ART was initiated in a private clinic were 
significantly advantaged in multiple respects in comparison with those who received public 
sector care48. Recent changes in the national guidelines mandating initiation of therapy at a 
much earlier stage of infection are likely to improve this situation significantly34,49,50. Despite 
this disadvantage however, our results are encouraging given the very high rate of 
immunological response in our subjects. Our findings support the belief that initiation of 
therapy at lower CD4 counts disadvantages patients. We showed a correlation between a low 
baseline CD4 count and the development of IRIS which approached statistical significance: 
the numbers were small and it is possible that a larger study would confirm this association. 
Furthermore, we have shown strong correlation between the CD4 count at 12 months and the 
baseline CD4 counts; recent evidence suggests that the lower CD4 counts achieved by 
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Characteristics at baseline. Values are expressed as mean (SD) or median [IQR]. Some patients 
had more than one opportunistic infection. 
 
 Total Male Female p 
N 257 71 (27.6%) 186 (72.4%) 0.001 
Age (years) 36.6 (SD 9.3) 36.6 (SD 9.0) 36.7 (SD 9.5)  0.94 
Baseline CD4 (cells/mm3) 139 [IQR 63-195] 90 [IQR 24-180] 148 [IQR 88-199] 0.0003 
Opportunistic infections 
(percentage of the total) 






Opportunistic infections noted prior to initiation of ART. 14 of the subjects had dual infection: 
TB and cryptococcal meningitis (9) and TB and candidiasis (2). 
 
Infection N 
Total 87 (33.9%) 
Cryptococcal meningitis 17 (6.6%) 
Tuberculosis (pulmonary and extrapulmonary) 68 (26.4%) 
Pulmonary tuberculosis 44 (17.1%) 
Extrapulmonary tuberculosis 17 (6.6%) 
Disseminated tuberculosis 7 (2.7%) 






Response to ART at 12 months. Values are expressed as mean (SD) or median [IQR]. 
 
 Baseline 12 months p 
CD4 (cells /mm3) (n=257) 139 [IQR 63-195] 327 [IQR 235-427] <0.0001 
Weight (kg) (n=253) 67.3 (SD 15.1) 71.4 (SD 15.4) <0.0001 
Haemoglobin (g/dL) 
(n=244) 






Response to ART at 12 months. Values are expressed as mean (SD) or median [IQR]. 
 
 Male Female p 
Increase in CD4 count 153 [IQR 115-223]  196 [IQR 131-278] 0.01 
Increase in weight 3.8 (SD 6.2) 4.1 (SD 6.7) 0. 69 
Increase in haemoglobin 
concentration 






CD4 change by CD4 count strata. Values are expressed as median [IQR]. 
 
CD4 Group N  Increment in CD4 count 
<50 56 186 IQR [IQR 118-254)] 
50-99 35 176 [IQR 128-257] 
100-199 110 175 [IQR 119-254] 
200-349 54 208 [IQR 149-296] 





There is a highly significant correlation between the CD4 count noted at the time of initiation 
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To investigate the rate of change of the CD4 count after commencing antiretroviral 
therapy(ART). 
BACKGROUND 
The CD4 count and viral load (RNA level) are closely linked to human immunodeficiency 
virus (HIV)-related illness and mortality. They provide prognostic information on HIV 
progression and on response to therapy. 
CD4 lymphocyte count 
The CD4+ T lymphocyte cells are the primary target of HIV. The CD4 count reflects the 
extent of immune suppression. It is calculated from the CD4 cell percentage and total white 
blood cell count. The normal values for the CD4 count vary considerably among different 
laboratories. The mean normal value for most laboratories is approximately 500-1,300 
cells/µL. In persons with untreated HIV infection, the CD4 count declines by approximately 
50-80 cells/µL per year on average. The pattern of decline is usually slow and steady, taking 
on average 10 years for a newly infected person to progress to acquired immunodeficiency 
syndrome (AIDS). There is however great variation among individuals. For some patients, 
disease progression occurs within a couple of years (rapid progressors) (Anzala et al., 1995). 
For others, it may take more than 20 years (slow progressors) (Rhodes et al., 2000). 
Among those with HIV infection, the CD4 lymphocyte count is the major indicator of 
immunodeficiency, a main factor in deciding whether to initiate antiretroviral therapy (ART), 
and an important parameter in monitoring treatment response (Joint United Nations 
Programme on HIV/AIDS (UNAIDS), 2010). Failure to restore a normal CD4 count following 
ART is associated with increased morbidity and mortality(Thompson et al., 2010). 
Prophylaxis against opportunistic infections is based on CD4 count, thus a CD4 count of less 
than 200 cells/µL is an indication for prophylaxis against Pneumocystis jiroveci pneumonia. 
The CD4 count  also guides decision making in determining when to stop prophylaxis against 
opportunistic infections in patients whose CD4 counts respond to ART. For monitoring 
purposes, the CD4 count should be repeated approximately every 3 to 6 months both in 
stable untreated patients and in patients on ART. It should however be checked more 
frequently in ART failure, in the face of a rapidly declining CD4 count and when switching 






The HIV-1 viral load measurement indicates the number of copies of HIV-1 RNA per millilitre 
of plasma. Although HIV ultimately resides within cells, the plasma measurement is an 
accurate reflection of the burden of infection and the magnitude of viral replication. It is 
critical in monitoring virologic response to therapy.  
Because CD4 and clinical responses may lag behind changes in viral load, viral load testing is 
essential for detecting virologic failure in a timely manner. With an effective ART regimen, 
suppression to undetectable levels should be achieved within 3 to 6 months after initiation 
of therapy(Kaplan et al., 2009).  
ART in South Africa 
South Africa has the highest HIV prevalence in the world, and additionally has the largest 
ART program(Lawn et al., 2009). From 2004 antiretroviral therapy was made available to all 
public sector adult patients with a CD4 count of less than 200 cells per µL and those with 
Stage 4 clinical disease.  
In  2010 the program  began to enrol pregnant and tuberculosis-co-infected subjects with a 
CD4 count of less than 350 cells/ml. More recently, in August 2011, the South African public 
health sector has implemented enrolment of all patients with a CD4 count of less than 350 
cells/µL  regardless of concurrent tuberculosis or pregnancy or clinical stage, as suggested in 
the World Health Organisation HIV Guidelines(World Health Organization, 2009). This will 
significantly reduce long term morbidity and mortality in the HIV-infected population 
though at the expense of an immediate financial strain. 
A typical first-line South African antiretroviral therapy regimen includes two nucleoside 
reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase 
inhibitor (NNRTI). Failure of this regimen may require switching to a protease inhibitor (PI)-
containing second line regimen. Patients with a CD4 count more than 350 are screened for 
opportunistic infections and AIDS defining illnesses. If none are found, the patient returns 
after 6 months for a repeat CD4 count. Patients at entry level are screened for hepatitis B, 
syphilis and active tuberculosis . Baseline CD4 cell count and biochemical profile including 
full blood count, renal and liver function tests are performed. Follow up is subsequently 
every 12 months for clinical and biochemical review. This entails screening for opportunistic 
infections and drug adverse effects. Of paramount importance is the 12 monthly monitoring 
of immunologic and virologic response, which involves monitoring of the CD4 count and 
viral load. 
A persistently low CD4 count and high HIV viral load in a compliant patient raises a question 
of viral resistance to therapy. Twelve months after initiation of antiretroviral therapy the 
viral load should be undetectable. However there are no strict guidelines stipulating the 
expected average increase in the CD4 count, below which one would be classified as having 




response, have been used. Suboptimal reconstitution has been defined as: an increase in 
CD4 count of less than 200 cells/mm3, or failure to attain an absolute CD4 count exceeding 
200 cells/mm (Hermans et al., 2010), failure to develop a more than 30% increase in CD4 
count or an absolute CD4 less than 200 cells/mm3 with full suppression of HIV 
replication(Gazzola et al., 2009) during the first 6–12 months of ART (Lifson et al., 2011). 
This is partly because ART-induced increases in CD4 cell count are much more variable from 
patient to patient than viral load.  In multivariate analysis adjusting for baseline CD4 and 
post-ART time interval, CD4 responses were lower in patients who met the following 
criteria: longer time from HIV seroconversion to initiation of ART, lower pre-ART CD4 nadir, 
higher pre-ART viral load and clinical AIDS before ART(P<0.05)(Lifson et al., 2011).  This 
study also demonstrated that the greatest CD4 changes occurred in the first 6 months post-
ART (with an average increase of 93-151 cells over baseline values), with lesser increases 
through the first four years (average increase of 22-36 cells per year).  
Four other studies worthy of mention have demonstrated variable responses in CD4 count 
after a year on ART. A study performed on 596 ART-naïve individuals in Cape Town, South 
Africa, demonstrated a increase from a median CD4 cell count of 97 cells/μL to 261 cell/ μL 
over 48 weeks (Lawn et al., 2006).  
In a pan-European observational study on 1835 ART-naïve individuals, the greatest mean 
yearly increase in CD4 count of 100 cells per μL was seen in the year after starting 
ART(Mocroft et al., 2007). In the Swiss-HIV Cohort Study, median CD4 T-cell increases 
following viral load suppression were 87 cells/ μL within 1 year of initiation of ART. This 
study also showed that median CD4 T-cell increases were higher for female gender, lower 
age and a higher viral load at ART start. Patients on tenofovir showed significantly lower 
increases compared with stavudine (Wolbers et al., 2007). In a study done in Botswana, on 
633 patients initiated on an non-nucleoside reverse transcriptase inhibitor-based 
combination of ART , the median CD4 increase was 169 cells/µL at 1 year(Hermans et al., 
2010). 
In other studies to evaluate prior ART experience and host characteristics as determinants 
of immunologic and virologic response to ART, better short- and long-term CD4 cell 
responses were observed in treatment-naive users. Intermittently and consistently 
experienced users did not significantly differ in response. Whereas race did not affect 
response, among those initiating ART with >400×10⁶ CD4 cells/l, younger age and the ∆32 
CCR5 genotype were associated with a better short term CD4 cell response (Yamashita et 
al., 2001). It has been suggested that zidovudine-containing regimens and male sex are also 
associated with lower responses (Hermans et al., 2010). 
It is also noteworthy that concurrent opportunistic infections, the commonest being 
tuberculosis, would be expected to blunt ART induced CD4 count improvement. In a study in 
Uganda , patients who developed tuberculosis in the first 24 months post-inception of 




factors associated with CD4 change at two years confirmed that incident tuberculosis during 
ART was associated with lower CD4 count recovery (Hermans et al., 2010).It would  be of 
much clinical value to study the trend in CD4 count in response to ART in a South African 
setting.  The aim is to incorporate the CD4 response as a guide in defining ART treatment 
failure. Using CD4 count as a tool is more feasible in our resource-limited setting as viral 
RNA is only done at the central virological laboratories, resulting in delayed turn-around 
times for results, and is additionally costly. On the other hand CD4 count analysers are more 
accessible as they are available even at district level hospitals. This study will also emphasize 
the importance of identifying immunological success in addition to virological suppression 
and optimizing treatment for immununological failure.   
AIM OF STUDY 
To investigate the rate of change in CD4 count over 12 months in patients recently initiated 
on ART. 
OBJECTIVES 
1. Assess CD4 and viral load response after the first 12 months of antiretroviral 
therapy. 
2. To investigate the impact of age, baseline CD4, HIV clinical stage, intercurrent 
infection(including  tuberculosis) and concurrent non-ART medication on 
immunologic response after 12 months of ART. 
DESIGN AND METHODS 
A retrospective chart review of patients enrolled at the Philani Clinic (the HIV clinic attached 
to King Edward VIII Hospital) will be carried out. This will comprise 250 patients enrolled for 
the first time on the ART programme at the clinic after January 2010. A record of their age, 
sex, baseline CD4 count, and regimen type will be documented at initiation and at 12 
months post-initiation of ART.  The presence of HIV related Stage 3 or 4 illnesses, and 
intercurrent infections that occur within 2 months prior to initiation of ART and within the 
12 months study period will be documented. This will include patients with tuberculosis(TB) 
and those who develop Immmune Reconstitution Inflammmatory Syndrome(IRIS) post-
initiation of ART.The variable of interest, which is, the change in CD4 count will be 
monitored and correlated with the viral load trend. 
Data will be analysed for correlations with demographic data (age, sex and race), presence 
of intercurrent infection(including TB), WHO HIV clinical stage, baseline CD4,  ART 




defined as missing any medication refill during the 12 months study period according to 
pharmacy records. This is with the assumption that patients who collect their medicine refill 
do take their pills at home. 
Inclusion criteria 
 Patients 18 years and older, commenced for the first time on ART from January 
2010,  who were subjected to clinical review, and immunologic and virologic 
monitoring 12 months after initiation of ART. 
Exclusion criteria 
 Patients with no data at 12 months 
 Documented psychiatric illness sufficient to alter expected treatment adherence. 
 Patients with documented poor adherence 
Sample size 
250 sequential patient clinical charts will be reviewed.  
Limitations of study 
1. Lack of physical patient interviews to assess adherence directly. 
2. Lack of means to assess the effect of genetic determinants (e.g. the protective 32 CCR5 
genotype) on CD4 response curves. 
3. Inavailability of baseline viral load , as this not performed in the public sector 
Data: Management and statistical analysis 
Patient data will be entered into a spreadsheet. Data will be analysed according to age,race, 
sex, baseline CD4, the presence of intercurrent  AIDS-related illnesses(other than 
tuberculosis), ART regimen and use of non-ART medication. Mean  change in CD4 countwill 
be documented, and statistical significance and confidence intervals determined where 
appropriate. 
Ethical considerations 
Specific consent will not be obtained from patients since this is a retrospective review. Data 
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